about
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010Right ventricular endomyocardial fibrosis (2013 Grover Conference series)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Presence of circulating anti-myosin antibodies in endomyocardial fibrosisDiagnosis and Management of Endomyocardial Fibrosis.Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives.The Medical Education Partnership Initiative (MEPI), a collaborative paradigm for institutional and human resources capacity building between high- and low- and middle-income countries: the Mozambique experience.Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué.World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease--an evidence-based guideline.Innovative strategies for transforming internal medicine residency training in resource-limited settings: the Mozambique experienceResearch capacity. Enabling the genomic revolution in Africa.Endomyocardial fibrosis: A form of endemic restrictive cardiomyopathyGenetic susceptibility to endomyocardial fibrosis.Rheumatic heart disease in Africa: is there a role for genetic studies?Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study).Cardiac Disease and HIV in Africa: A Case for Physical Exercise.Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.Neglected tropical cardiomyopathies: I. Chagas disease: myocardial disease.Neglected tropical cardiomyopathies: II. Endomyocardial fibrosis: myocardial disease.Neglected diseases in cardiology: a call for urgent action.'Longitudinal' topics in Cardiovascular Diagnosis and Therapy (CDT).Lack of focus on cardiovascular disease in sub-Saharan Africa.African experiences of humanitarian cardiovascular medicine: the Mozambican experienceFocus on non-communicable diseases: an important agenda for the African continent.Strengthening research capacity through the medical education partnership initiative: the Mozambique experienceForgotten cardiovascular diseases in Africa.Family reintegration of homeless in Maputo and Matola: a descriptive studyWomen's cardiovascular health in Africa.A global perspective on the epidemiology of pulmonary hypertension.Impact of Socioeconomic Status, Ethnicity, and Urbanization on Risk Factor Profiles of Cardiovascular Disease in Africa.An innovative technique for the relief of right ventricular trabecular cavity obliteration in endomyocardial fibrosis.The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD.
P50
Q21534928-13DFB1AD-5075-4748-B702-EEBF2E5D1208Q21534928-654E626A-3965-40A6-B34D-61392B1BF774Q27860791-BCD6CC5E-4FC5-40BD-86B4-8B5D1C2F6760Q28084339-08568C30-3782-463C-8F2A-ED4412CEEF8EQ28111913-67BBD465-AD86-408E-9EB1-F28CF91DC910Q28111913-A0894710-BD63-44B7-860A-CE4D543EF3B2Q28473727-0A7E1D13-84B9-4E2C-9EB9-BD1D2796CAD6Q30240648-9FFDBF4E-E01F-4E95-B145-4F4F66AF470DQ30249643-30F45D6F-3AA2-4244-BFB0-80C82832EE9CQ30378422-77411027-62F3-404A-913B-5E944E4725FDQ30380113-DB0042DD-3360-40D8-80EC-7015DAA51A39Q33924517-551E08B3-807B-45D6-A5A4-D37E41ABA75FQ33977718-9837D002-0482-4F65-9210-29541B5275D8Q34068017-1D7D61D3-6CC2-4EB2-B940-44819B66A5ECQ34553695-98F02AB1-5B52-468C-8344-2F5B9EB85054Q35165122-790DD406-BA34-414E-AD11-3985B662B4E0Q36059771-F1EC1385-E9B2-4C5B-A095-FFB41E1ABD4DQ36153014-A702D44D-9089-4BDC-99DB-0D0E2FE4B10BQ36282421-9C83446B-56FE-4EFF-9196-479B4FFC51E1Q36734230-E8B16E12-98BC-49C8-AC83-1A9A67D3EF18Q37057002-326BD088-B727-420B-B05E-67025486F30AQ37085261-98B8E52D-A579-422A-ACFF-4D3BF850D0EAQ37101215-863F2259-6D6C-4E6A-9BA6-4BF71CEE038BQ37339289-0DA3B8F7-22D0-4560-8795-0EEDFE3B0D26Q37339350-01C1BE61-7E34-4271-8245-7003BF00B5F6Q37339370-E1A2B510-C302-4E14-A39D-99DED02F88DFQ37425551-C4D1C398-109F-4F8C-8EAE-F807FF6BDA71Q37493926-9A1D2517-4708-4498-AFF9-F9B34FC0E028Q37655218-452317FA-05FD-4607-A209-2398CE4F7A50Q37748100-8720F315-4A04-400E-956A-0ABB16BEEBF9Q37986456-1AC649E2-8D1B-489D-B0DB-7BE0CEF2D919Q38404252-392924E7-8177-4D51-96A2-DA365D34309CQ38784411-96D2653F-D3BE-4B54-818D-4E1046FE39C9Q39329630-E64A53DB-C171-4C89-AD11-01DD53A096CDQ39334449-8DAD525B-92BC-435F-B358-ED19042270E6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ana Olga Mocumbi
@ast
Ana Olga Mocumbi
@en
Ana Olga Mocumbi
@es
Ana Olga Mocumbi
@nl
Ana Olga Mocumbi
@sl
type
label
Ana Olga Mocumbi
@ast
Ana Olga Mocumbi
@en
Ana Olga Mocumbi
@es
Ana Olga Mocumbi
@nl
Ana Olga Mocumbi
@sl
prefLabel
Ana Olga Mocumbi
@ast
Ana Olga Mocumbi
@en
Ana Olga Mocumbi
@es
Ana Olga Mocumbi
@nl
Ana Olga Mocumbi
@sl